Serum amyloid A as a sensitive marker of disease activity in rheumatic diseases
DOI:
https://doi.org/10.15305/ijrci/v2iS1/71Keywords:
Serum Amyloid A, Acute phase reactants, inflammation, rheumatological diseasesAbstract
Inflammation is known to play a major role in rheumatologic disorders. Hence quantitating the degree of inflammation has become essential to tailor the treatment strategy, especially with the discovery of potent biologicals. CRP and ESR are the currently used predominant inflammatory markers for rheumatologic disorders, but they have several limitations. Various studies have highlighted the superiority of serum amyloid A over these markers in quantitating inflammatory and treatment responses. With the widespread availability of ELISA kits, it has become necessary to implicate its use in day to day clinical practice.
References
Maksymowych WP, Landewe R, Boers M, Garnero P, Geusens P, El-Gabalawy H, et al. Development of draft validation criteria for a soluble biomarker to be regarded as a valid biomarker reflecting structural damage endpoints in rheumatoid arthritis and spondyloarthritis clinical trials. J Rheumatol. 2007 Mar;34(3):634–40.
Gabay C, Kushner I: Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999; 340: 448-454.
Cha C-H, Park C-J, Cha YJ, Kim HK, Kim DH, Honghoon, et al. Erythrocyte sedimentation rate measurements by TEST 1 better reflect inflammation than do those by the Westergren method in patients with malignancy, autoimmune disease, or infection. Am J Clin Pathol. 2009 Feb;131(2):189–94.
Vanderschueren S, Deeren D, Knockaert DC, Bobbaers H, Bossuyt X, Peetermans W. Extremely elevated C-reactive protein. Eur J Intern Med. 2006 Oct;17(6):430–3.
Volanakis JE. Human C-reactive protein: expression, structure and function. Mol Immunol. 2001; 38: 189-197.
Woloshin S, Schwartz LM. Distribution of C-reactive protein values in the United States. N Engl J Med 2005; 352: 1611-1613.
Vlam KD. Soluble and Tissue Biomarkers in Ankylosing Spondylitis. Best Practice & Research Clinical Rheumatology. 2010; 24:671–682.
Ruof J, Stucki G. Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review. J Rheumatol 1999; 26:966–70.
Malle E, De Beer FC. Human serum amyloid A (SAA) protein: a prominent acute phase protein for clinical practice. Eur J Clin Invest. 1996; 26: 427-435.
Cheng N, He R, Tian J, Ye PP, Ye RD. Cutting edge: TLR2 is a functional receptor for acute-phase serum amyloid A. J Immunol. 2008 Jul 1;181(1):22–6.
He R, Shepard LW, Chen J et al: Serum amyloid A (SAA) is an endogenous ligand that differently induces IL-12 and IL-23. J Immunol. 2006; 177: 4072-79.
Mullan RH, Bresnihan B, Golden-Mason L, Markham T, O’Hara R, FitzGerald O, et al. Acute-phase serum amyloid A stimulation of angiogenesis, leukocyte recruitment, and matrix degradation in rheumatoid arthritis through an NF-kappaB-dependent signal transduction pathway. Arthritis Rheum. 2006 Jan;54(1):105–14.
Shah C, Hari-Dass R, Raynes JG. Serum amyloid A is an innate immune opsonin for gram-negative bacteria. Blood. 2006; 108: 1751-1757.
Spoorenberg A, van der Heijde D, de Klerk E, Dougados M, de Vlam K, Mielants H, et al. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol. 1999 Apr;26(4):980–4.
Jung SY, Park MC, Park YB, Lee SK. Serum amyloid A as a useful indicator of disease activity in patients with ankylosing spondylitis. Yonsei Med J. 2007;48:218–24.
De Vries MK, van Eijk IC, van der Horst-Bruinsma IE, Peters MJL, Nurmohamed MT, Dijkmans BAC, et al. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis. Arthritis Rheum. 2009 Nov 15;61(11):1484–90.
Lange U, Boss B, Teichmann J, Klor HU, Neeck G. Serum amyloid A: an indicator of inflammation in ankylosing spondylitis. Rheumatol Int. 2000;19:119–22.
Chambers RE, MacFarlane DG, Whicher JT, Dieppe PA. Serum amyloid-A protein concentration in rheumatoid arthritis and its role in monitoring disease activity. Ann Rheum Dis. 1983 Dec;42(6):665–7.
Grindulis KA, Scott DL, Robinson MW, Bacon PA, McConkey B. Serum amyloid A protein during the treatment of rheumatoid arthritis with second-line drugs. Br J Rheumatol. 1985 May;24(2):158–63. Hara RO, Murphy EP, Whitehead AS, FitzGerald O, Bresnihan B. Acute-phase serum amyloid A production by rheumatoid arthritis synovial tissue. Arthritis Res 2000; 2:142–144.
Connolly M, Mullan RH, McCormick J. Acute-Phase Serum Amyloid A regulates tumor necrosis factor-α and matrix turnover and predicts disease progression in patients with inflammatory arthritis before and after biologic therapy. Arthritis and rheumatism. 2012; 64(4): 1035–1045.
Hernández-Rodríguez J, Cid MC, López-Soto A, Espigol-Frigolé G, Bosch. Treatment of polymyalgia rheumatica: a systematic review. Arch. Intern. Med 2009; 169 (20): 1839–50.
Hachulla E, Saile R, Parra HJ, Hatron PY, Gosset D, Fruchart JC, et al. Serum amyloid A concentrations in giant-cell arteritis and polymyalgia rheumatica: a useful test in the management of the disease. Clin Exp Rheumatol. 1991 Apr;9(2):157–63.
Yamane T, Yamauchi H, Abe N, Torio N, Shimada R, Senba T, et al. [Serum amyloid A as a useful index of disease activity in polymyalgia rheumatica]. Ryumachi. 2003 Jun;43(3):544–8.
Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. American Journal of Respiratory and Critical Care Medicine 2011;183 (5): 573–81.
Bargagli E, Magi B, Olivieri C, Bianchi N, Landi C, Rottoli P. Analysis of serum amyloid A in sarcoidosis patients. Respir Med. 2011 May;105(5):775–80.
Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004 Feb;31(2):390–2.
Cantarini L, Giani T, Fioravanti A, Iacoponi F, Simonini G, Pagnini I, et al. Serum amyloid A circulating levels and disease activity in patients with juvenile idiopathic arthritis. Yonsei Med J. 2012 Sep;53(5):1045–8.
Additional Files
Published
Issue
Section
License
Copyright for articles published in this journal is retained by the authors, with first publication rights granted to the ‘Internet Journal of Rheumatology and Clinical Immunology’. All the published content, except where otherwise noted, is licensed under Creative Commons license (CC-BY).
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) after the publication of the manuscript in IJRCI, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
